ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 109

Tarsitis in Juvenile Idiopathic Arthritis: Clinical characteristics, imaging features, and treatment Response – A multicenter retrospective study

naiera assalia1, Leraz Tobias2, Yoel Levinsky1, gil amarilyo1, Yonatan Butbul Aviel2, Liora Harel1 and Mohamad Hamad Saied3, 1Schneider Children's Medical Center of Israel, 2Rambam Medical Centre, Haifa,Israel, 3Carmel medical centre, Haifa, Israel

Meeting: 2026 Pediatric Rheumatology Symposium

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Friday, March 20, 2026

Title: Posters: Clinical and Therapeutic Aspects II

Session Time: 5:00PM-6:00PM

Background/Purpose: Tarsitis is defined as inflammation of intertarsal joints, overlying tendons, entheses and soft tissue and is often under-recognized particularly in pediatrics. Our aim is to characterize clinical features, imagin findings, and treatment response of tarsitis in juvenile idiopathic arthritis (JIA).

Methods: Retrospective multicenter cohort (2014-–2025) included JIA patients with tarsitis, Patients were grouped as isolated tarsitis vs tarsitis with additional joint involvement. Primary outcomes were treatment failure rate to first line DMARDS.

Results: Thirty-nine patients were included (69% female); 11 had isolated tarsitis and 28 had additional joint involvement. Mean age at tarsitis onset was 7.1 years. Polyarticular JIA (51%) and ERA (23%) were the most frequent categories. Most patients initiated MTX (87%); the majority (76.5%) required escalation to biologics. First-line anti-TNF therapy achieved high rates of remission. Compared with other involved joints, tarsitis showed greater MTX non-response with P value < 0.032 ,and odds ratio 4.44 (95% CI 1.17–16.92). Median time to inactive tarsitis was 8–9 months

Conclusion: This multicenter cohort demonstrates that tarsitis represents a distinct and challenging manifestation of JIA, often presenting early, with female predominance, frequent ANA positivity, and a high rate of MTX resistance compared with other joints. Our results, together with the limited literature, suggest that tarsitis should be recognized as a high-risk feature warranting early escalation to biologic therapy. Current ACR/EULAR guidelines do not specifically address tarsal involvement, and our data provides a rationale for its inclusion in future treatment recommendations


Disclosures: n. assalia: None; L. Tobias: None; Y. Levinsky: None; g. amarilyo: None; Y. Butbul Aviel: None; L. Harel: None; M. Hamad Saied: None.

To cite this abstract in AMA style:

assalia n, Tobias L, Levinsky Y, amarilyo g, Butbul Aviel Y, Harel L, Hamad Saied M. Tarsitis in Juvenile Idiopathic Arthritis: Clinical characteristics, imaging features, and treatment Response – A multicenter retrospective study [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 3). https://acrabstracts.org/abstract/tarsitis-in-juvenile-idiopathic-arthritis-clinical-characteristics-imaging-features-and-treatment-response-a-multicenter-retrospective-study/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to 2026 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tarsitis-in-juvenile-idiopathic-arthritis-clinical-characteristics-imaging-features-and-treatment-response-a-multicenter-retrospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology